The use of dabigatran, a non-vitamin K antagonist (VKA) oral anticoagulant, is still increasing. Dabigatran has a good efficacy and safety ratio, as well as a more predictable anticoagulation effect compared with VKA. On the other hand, there is acenocoumarol/warfarin, a VKA which was evaluated in numerous clinical trials and is a drug of choice in a valve-related atrial fibrillation (AF).
Introduction
Oral anticoagulant therapy is commonly used in an everyday practice. However, clinicians have to deal with a thrombotic and bleeding risk, which frequently is problematic, especially in patients requiring invasive treatment. Currently no evidence-based guidelines are available for periprocedural complications in anticoagulated patients. Pulmonary vein isolation (PVI) of atrial fibrillation (AF) and implantation of cardiac rhythm devices are associated with a 1-2% risk of serious bleedings (tamponade, hemothorax) and 5% of minor bleedings (groin bleedings, hematomas). However, incidence of those complications is decreasing in recent trials [1] .
Dabigatran, as a non-vitamin K antagonist (VKA) oral anticoagulant (NOAC), is a treatment of choice for thrombo--embolic prevention in patients with a non-valvular AF [1] . The aim of this paper was to summarize the principles of management of periprocedural complications, during different oral anticoagulant treatment. We presented two cases of patients using dabigatran (treated with PVI) and one case of a patient using acenocoumarol after ICD implantation.
Case details

Case 1
A 64-year-old female with persistent AF was admitted for PVI. Medical history included arterial hypertension and obesity, with normal renal and liver function. The patient was assessed on 2 points in CHA 2 DS 2 VASc score and on 1 point in HAS-BLED score. AF, lasting from about 3 years, was symptomatic (EHRA III, European Heart Rhythm Association). Before admission, the patient was receiving perindopril, bisoprolol, spironolactone, propafenone and dabigatran (150 mg bid). On presentation, her vitals were: blood pressure (BP) 140/90 mm Hg, pulse was irregulararound 90 bpm. Clotting times were normal. On the second day of the hospitalization the patient underwent a PVI and was admitted in a good general condition to intensive cardiac care unit for monitoring. After eight hours of the pressure bandage observation, hematoma appeared in the right groin ( Figure 1A ). Cardiovascular examination showed signs of a hemorrhagic shock: tachycardia -100 bpm, BP 100/60 mm Hg. Laboratory findings were: red blood cells (RBC) -2.82 × 10 6 /μl (baseline: 4.22 × 10 6 /μl) and hemoglobin -8.3 g/dl (baseline: 12.7 g/dl). At that time the patient received aggressive IV fluid replacement. In the following few hours, further decrease of blood parameters was observed: RBC -2.34 × 10 6 /μl, hemoglobin -7.2 g/dl and hematocrit -21.1%. Group and cross-match was taken. The patient was transfused one unit of packed RBC (PRBC), with poor outcome and in the next day another two units, reaching RBC -3.2 × 10 6 /μl and hemoglobin 10.0 g/dl. Her BP improved to 132/69 mm Hg and pulse to 85 bpm.
Large intramuscular hematoma with three compartments (the largest was 64 × 20 × 54 mm) ( Figure 1B ) was revealed in USG of the right groin. It was concluded that the bleeding was likely an adverse effect of a daily dabigatran therapy. Dabigatran was continued through the hospitalization except the ablation day. During further hospitalization a control USG study confirmed hematoma absorption and the patient was discharged in a good general condition.
Case 2
A 79-year-old man with dilated cardiomyopathy and severe heart failure was readmitted 14 days after implantation (9 days after discharge) of a single-chamber cardioverter--defibrillator (ICD) with a pocket hematoma. Relevant medical history included: chronic acenocoumarol treatment due to persistent AF, chronic kidney disease stage G3b, post-thrombotic syndrome and percutaneous mitral valve repair with MitraClip. Before admission, the patient received furosemide, ramipril, carvedilol, eplerenone, allopurinol and acenocoumarol (4 mg OD). On presentation, large hematoma with a superficial bruise on the anterior chest was seen (Figure 2A ). The patient did not suffer from chest pain or shortness of breath. His vitals were: BP 93/62 mm Hg and irregular pulse -around 75 bpm. Laboratory findings were: hemoglobin -10.7 g/dl (last known: 11.24 g/dl), platelets -253 × 10 3 /μl (normal range 150-400 × 10 3 /μl), creatinine -1.52 mg/dl, INR -2.21, prolonged APTT -52.9 s. USG of the chest revealed a large pocket hematoma with dimensions 42 × 48 × 8 mm ( Figure 2B ). Firstly, a sterile compression therapy was applied. It was concluded that hematoma was likely an adverse effect of acenocoumarol, which was wherefore suspended and replaced by enoxaparine (80 mg od) after one day cessation of the anticoagulation therapy. On consecutive day the hematoma was evacuated. After 2 weeks of the further hospitalization the hematoma absorption was observed and acenocoumarol was then gradually restarted with a low dose (2 mg). The patient was discharged in a good general condition, with the recommendations of INR level check every 2-3 weeks. Figure 3B ). Consulting vascular surgeon applied a percutaneous injection of thrombin into the pseudoaneurysm cavity, without dabigatran suspension. Clotting of the pseudoaneurysm was obtained. The patient was discharged 3 days after ablation without any complications.
Discussion
High dose (150 mg bid) of dabigatran has an improved efficacy and comparable safety ratio, does not require routine monitoring because of a predictable effect, fewer food and drug interactions, compared with VKA [1] , as presented in Table 1 . Dabigatran and warfarin (which was used in most of the clinical trials comparing VKA drugs, but it has similar characteristics to acenocoumarol) have similar numbers of thrombo-embolic and bleeding events in patients undergoing PVI of AF and implantation of cardiac rhythm devices [2, 3] . Consensus statement recommended uninterrupted
Case 3
A 66-year-old man, with a paroxysmal AF and atrial flutter was admitted to the hospital for a transcutaneous radiofrequency ablation of the arrhythmia. The symptoms were assessed as EHRA III. Medical history included stable coronary artery disease, arterial hypertension, diabetes mellitus type 2, hyperthyroidism, and hyperlipidemia. Renal and liver function were normal. The patient was assessed on 3 points in CHA 2 DS 2 VASc score and on 2 points in HAS-BLED score. The patient before admission was receiving valsartan, metoprolol, metformin, gliclazide, dabigatran (150 mg bid, it was continued through the hospitalization except the ablation day). On presentation, his vitals were: BP 135/70 mm Hg, pulse was irregular -around 72 bpm. Next day after ablation, after removal of the pressure dressing, skin bruise was presented ( Figure 3A ). Furthermore murmur and severe pain in the right groin was found. Control US study revealed a femoral artery pseudoaneuysm (FAP) (38 × 30 × 15 mm) VKA treatment (with target INR 2.0-2.5) performing PVI because of lower rate of thrombo-embolic and bleeding events (compared with interrupted treatment) [4] . Recently dabigatran demonstrated similar safety to warfarin, giving the opportunity for continuous proceeding with OAC [4] , but still it is recommended to stop dabigatran ≥ 24 h prior to a procedure.
In the 1 st case, there was presented intramuscular bleeding after right femoral vein puncture for PVI. A bleeding risk of our patient was assessed as low and according to the recommendations, dabigatran was stopped 24 h before the PVI (Table 2 ) [1] . It is suggested that the activated partial thromboplastin time (APTT) independently predict periprocedural complications in the dabigatran group [5] ; however, clotting times of our patient before procedure were normal and after were unknown. During the ablation, the active clotting time (ACT) test is used because of high heparin doses and that APTT is too sensitive [1] . ACT should achieve 300-350 s in NOAC-or VKA-treated patients [1] . Dabigatran can be restarted 3-4 h after sheath removal in patients with an adequate hemostasis and the absence of a pericardial effusion [1] . Maximal anticoagulation effect is achieved within 2 h of ingestion [1] . Despite a low bleeding risk, our patient had a major bleeding (hemoglobin dropped to 7.2 g/dl) requiring transfusion of 3 PRBC units (proceedings in dabigatran-related bleedings are Figure 4 ). From recent idarucizumab approval, there is a possibility of rapid reverse of the dabigatran anticoagulant action, in case of a need for an emergent surgery or a life-threatening bleeding [1] . However, at that time idarucizumab was still unavailable in our hospital and probably it would not change the prognosis of the patient. Dabigatran was continued since next day after ablation when hemoglobin concentration stabilized. A pocket hematoma is an acute complication after a device implantation [6] . It occurs in 2-4% of cases, but the risk is increased in anticoagulated patients (up to 12-23%) [6] . The 2 nd case presented a patient with a pocket hematoma developed over few days after ICD implantation. This patient required an adequate anticoagulation because of a valvular-AF and a post-thrombotic syndrome. However, he had also an increased risk of a VKA-related bleeding due to advanced age, severe heart and renal failure. His INR level was appropriate (2.21) but he had prolonged APTT (52.9 s). In consequence, the bleeding exacerbated anemia and acenocoumarol was suspended (proceedings in planned procedures and bleedings on acenocoumarol treatment are shown in Table 3 and Figure 5 , respectively). Because of a considerable size of hematoma, our patient required a surgical intervention. Based on the literature, surgical hematoma evacuation is required in 1-2% [6] . Pocket hematoma related to device implantation is also associated with an increased risk of infection and often leads to prolonged hospital stays [6] .
The 3 rd case presented a FAP in the right groin of a patient who underwent transcutaneous radiofrequency ablation. A FAP is one of the most undesirable complications after invasive procedures and its incidence is still increasing [7] . A FAP is associated with anticoagulation and there is a need for further research on the use of •PCC 50 U/kg; +25 U/kg •aPCC 50 U/kg; max 200 U/kg/day •rFVIIIa 90 μg/kg Table 3 dabigatran in patients with a FAP [7] . In our patient a FAP appeared on the next day after ablation. The probability of a spontaneous FAP closure remarkably decreases in patients on anticoagulation and it usually needs a thrombin injection [7] . Conservative treatment can be used in not anticoagulated patients with small (< 2 cm) and asymptomatic pseudo-aneurysms [7] . FAP due to a severe pain and large dimensions (> 3 cm, which is a significant risk of a pseudoaneurysm rupture [7] ) required an intervention. In patients with normal creatinine clearance and with a low risk of bleeding, interventions can be performed 12-24 h after the last dabigatran intake ( Table 2 ) [1] . However, our case confirms a possibility of a successful pseudoaneurysm closure without dabigatran suspension, which is consistent with Dzijan-Horn et al. recommendations [8] .
Conclusions
Periprocedural oral anticoagulation depends on the anticoagulant type and requires individual assessment of the patient's thromboembolic and bleeding risk factors. Our study shows that in case of a bleeding, dabigatran may be quickly stopped and then restarted recently after reaching hemostasis, in contrast to acenocoumarol. It also confirms a possibility of a successful pseudoaneurysm closure without dabigatran suspension.
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Streszczenie
Zastosowanie dabigatranu, doustnego antykoagulantu niebędącego antagonistą witaminy K, jest coraz powszechniejsze. Z jednej strony dabigatran cechuje się dobrą skutecznością i bezpieczeństwem, a także bardziej przewidywalnym działaniem przeciwzakrzepowym niż antagoniści witaminy K. Z drugiej strony jest acenokumarol/warfaryna, antagonista witaminy K, który oceniano w wielu badaniach klinicznych -lek z wyboru w zastawkowym migotaniu przedsionków. Na podstawie przypadków klinicznych autorzy starali się podsumować aktualne zalecenia postępowania w przypadku okołozabiegowych powikłań podczas doustnego leczenia przeciwkrzepliwego. W 1. przypadku zaprezentowali pacjenta stosującego dabigatran, poddanego izolacji żył płucnych, u którego po zabiegu wystąpił krwiak prawej pachwiny i w konsekwencji chory wymagał kilku transfuzji krwi. W 2. przypadku opisali pacjenta stosującego acenokumarol, z wysokim ryzykiem krwawienia, u którego pojawił się krwiak loży pooperacyjnej po implantacji kardiowertera-defibrylatora. Przedstawiono również pacjenta poddanego terapii dabigatranem, u którego wystąpił tętniak rzekomy prawej tętnicy udowej po zabiegu izolacji żył płucnych.
Okołozabiegowa doustna antykoagulacja zależy od rodzaju antykoagulantu oraz wymaga indywidualnej weryfikacji czynników ryzyka krwawienia i prozakrzepowych u danego pacjenta. Opisy tych przypadków pokazały, że jeśli wystąpi krwawienie, to dabigatran można szybko odstawić i ponownie włączyć niedługo po osiągnięciu hemostazy, w przeciwieństwie do acenokumarolu. Potwierdzają one również możliwość pomyślnego zamknięcia tętniaka rzekomego bez odstawiania dabigatranu.
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